Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
4.270
-0.230 (-5.11%)
Dec 5, 2025, 4:00 PM EST - Market closed
Lyra Therapeutics Employees
Lyra Therapeutics had 30 employees as of December 31, 2024. The number of employees decreased by 58 or -65.91% compared to the previous year.
Employees
30
Change (1Y)
-58
Growth (1Y)
-65.91%
Revenue / Employee
$20,000
Profits / Employee
-$1,098,233
Market Cap
7.58M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LYRA News
- 23 days ago - Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - GlobeNewsWire
- 4 months ago - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 6 months ago - Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
- 6 months ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
- 6 months ago - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewsWire
- 7 months ago - Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewsWire